Boston Scientific Co. (NYSE:BSX) Position Reduced by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ reduced its position in Boston Scientific Co. (NYSE:BSX) by 0.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 940,760 shares of the medical equipment provider’s stock after selling 4,631 shares during the period. Skandinaviska Enskilda Banken AB publ owned about 0.06% of Boston Scientific worth $84,367,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Impax Asset Management Group plc raised its stake in Boston Scientific by 17.5% during the 3rd quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider’s stock valued at $457,138,000 after purchasing an additional 815,403 shares during the period. Mesirow Financial Investment Management Inc. acquired a new position in Boston Scientific during the third quarter valued at $222,000. Sigma Planning Corp raised its position in Boston Scientific by 5.2% during the third quarter. Sigma Planning Corp now owns 7,900 shares of the medical equipment provider’s stock valued at $662,000 after buying an additional 389 shares during the period. Venturi Wealth Management LLC lifted its stake in Boston Scientific by 62.5% in the 3rd quarter. Venturi Wealth Management LLC now owns 1,799 shares of the medical equipment provider’s stock worth $151,000 after acquiring an additional 692 shares in the last quarter. Finally, Harbour Investments Inc. grew its stake in Boston Scientific by 11.5% during the 3rd quarter. Harbour Investments Inc. now owns 2,817 shares of the medical equipment provider’s stock valued at $236,000 after acquiring an additional 291 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of research analyst reports. Raymond James increased their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a research report on Thursday, February 6th. Stifel Nicolaus lifted their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 8th. Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a report on Monday, March 3rd. Finally, Argus set a $130.00 target price on Boston Scientific in a research note on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $108.91.

Boston Scientific Stock Up 0.9 %

Shares of BSX opened at $96.42 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The company has a 50-day simple moving average of $100.80 and a 200-day simple moving average of $91.52. Boston Scientific Co. has a 52 week low of $65.52 and a 52 week high of $107.17. The firm has a market capitalization of $142.29 billion, a P/E ratio of 77.14, a P/E/G ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, equities research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares in the company, valued at $560,103.60. This trade represents a 75.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 1,201 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $106.31, for a total transaction of $127,678.31. Following the sale, the executive vice president now owns 25,443 shares of the company’s stock, valued at $2,704,845.33. The trade was a 4.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 137,302 shares of company stock worth $14,319,269 in the last 90 days. 0.50% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.